CAS 648904-28-3|Bavituximab
Introduction：Basic information about CAS 648904-28-3|Bavituximab, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
| Common Name | Bavituximab | ||
|---|---|---|---|
| CAS Number | 648904-28-3 | Molecular Weight | / |
| Density | / | Boiling Point | / |
| Molecular Formula | / | Melting Point | / |
| MSDS | / | Flash Point | / |
Names
| Name | Bavituximab |
|---|
Bavituximab BiologicalActivity
| Description | Bavituximab (Anti-Human Phosphatidylserine Recombinant Antibody) is a phosphatidylserine (PS)-targeting monoclonal antibody, suppresses tumor growth by targeting tumor vasculature and reactivating antitumor immunity. Bavituximab plus Paclitaxel (HY-B0015) and Carboplatin (HY-17393), have enhanced inhibition on non-small-cell lung cancer[1]. |
|---|---|
| Related Catalog | Research Areas >>CancerSignaling Pathways >>Others >>Others |
| Target | Phosphatidylserine (PS)[1] |
| In Vitro | Bavituximab binds to exposed phosphatidylserine (PS) molecules via the serum protein, β2-glycoprotein 1 (β2GP1)[1]. Bavituximab binds PS to induces antibody-dependent cellular cytotoxicity, resulting in tumor vessel destruction[1]. Bavituximab (10 μg/mL; 48 h) binds to exposed phosphatidylserine (PS) via 10 μM Sorafenib inducing exposure in HUVEC and bEnd.3 cells[2]. |
| In Vivo | Sorafenib induces exposure of anionic phospholipids in tumor model in mice. Bavituximab (100 μg/mouse; i.v.; single dose; 48 h after Sorafenib treatment) traces phosphatidylserine exposure in vivo[2]. Animal Model: Mice bearing subcutaneous PLC/PRF/5, C3A, and Huh7 tumors[2] Dosage: 100 μg/mouse (Bavituximab/β2GP1) Administration: Intravenous injection single dose; 48 h after sorafenib treatment (100 mg/kg; p.o.; single dose) Result: Traced phosphatidylserine exposure in vivo in mice with tumors. |
| References | [1]. Digumarti R, et al. Bavituximab plus paclitaxel and carboplatin for the treatment of advanced non-small-cell lung cancer. Lung Cancer. 2014 Nov;86(2):231-6. [2]. Cheng X, et al. Antibody-Mediated Blockade of Phosphatidylserine Enhances the Antitumor Effect of Sorafenib in Hepatocellular Carcinomas Xenografts. Ann Surg Oncol. 2016 Dec;23(Suppl 5):583-591. |
Chemical & Physical Properties
| No Any Chemical & Physical Properties |
